Get started
Author

Guowen Yin

Observed names: Guo-Wen Yin, Guo-wen Yin, GuoWen Yin, Yin, Guo-Wen
Observed institutions: University of Science and Technology of China, Sichuan Cancer Hospital, Jiangsu Cancer Hospital, Jiangsu Province Hospital, Beijing Tsinghua Chang Gung Hospital, Nanjing Medical University
ORCID: 0009-0000-5469-0105
Observed ORCIDs: 0009-0000-5469-0105, 0000-0002-5049-0568
OpenAlex ID: A5111226835
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
2021 · Zhenggang Ren, Jianming Xu, et al. · The Lancet Oncology · 1,190
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
2020 · Jianming Xu, Jie Shen, et al. · Clinical Cancer Research · 587
PDF
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)
2023 · Hai-Dong Zhu, Hai-Liang Li, et al. · Signal Transduction and Targeted Therapy · 320
Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study
2019 · Qiuhe Wang, Dongdong Xia, et al. · Journal of Hepatology · 270
Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)
2022 · Hui-Chuan Sun, Jian Zhou, et al. · HepatoBiliary Surgery and Nutrition · 218
PDF
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study
2024 · Zhi-Cheng Jin, Jian-Jian Chen, et al. · EClinicalMedicine · 192
Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study
2023 · Zhi-Cheng Jin, Bin-Yan Zhong, et al. · European Radiology · 105
PDF
Comparison on hypoglycemic and antioxidant activities of the fresh and dried Portulaca oleracea L. in insulin-resistant HepG2 cells and streptozotocin-induced C57BL/6J diabetic mice
2014 · Jun-fei Gu, Zhi-yin Zheng, et al. · Journal of Ethnopharmacology · 78
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
2025 · Jian Zhou, Li Bai, et al. · The Lancet Oncology · 77
Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations
2023 · Ming Zhao, Zhi Guo, et al. · Hepatology International · 71
Correlation and efficacy of TACE combined with lenvatinib plus PD ‐1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features
2023 · Xinhua Zou, Qingyu Xu, et al. · Cancer Medicine · 53
PDF
Regulation of different components from Ophiopogon japonicus on autophagy in human lung adenocarcinoma A549Cells through PI3K/Akt/mTOR signaling pathway
2017 · Juan Chen, Jiarui Yuan, et al. · Biomedicine & Pharmacotherapy · 48
Irradiation stent with 125I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial
2023 · Jian Lu, Jin-He Guo, et al. · International Journal of Surgery · 32
Nomogram and Artificial Neural Network for Prognostic Performance on the Albumin-Bilirubin Grade for Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
2019 · Bin-Yan Zhong, Cai-Fang Ni, et al. · Journal of Vascular and Interventional Radiology · 29
Angiogenesis for tumor vascular normalization of Endostar on hepatoma 22 tumor-bearing mice is involved in the immune response
2018 · Qingyu Xu, Junfei Gu, et al. · Oncology Letters · 25
PDF
Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study
2022 · Ran You, Qingyu Xu, et al. · Frontiers in Oncology · 24
PDF
Clinical Therapeutic Effect and Biological Monitoring of p53 Gene in Advanced Hepatocellular Carcinoma
2011 · Shixi Chen, Jun Chen, et al. · American Journal of Clinical Oncology · 24
Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study
2020 · Zhexuan Wang, Enxin Wang, et al. · Liver Cancer · 23
PDF
Resolvin D1 inhibits the proliferation of lipopolysaccharide‑treated HepG2 hepatoblastoma and PLC/PRF/5 hepatocellular carcinoma cells by targeting the MAPK pathway
2018 · You Lu, Qingyu Xu, et al. · Experimental and Therapeutic Medicine · 22
PDF
Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204)
2025 · Zhi-Cheng Jin, Jingwei Wei, et al. · Hepatology · 21
Hepatic arterial infusion chemotherapy combined with lenvatinib and PD‐1 inhibitors versus lenvatinib and PD‐1 inhibitors for HCC refractory to TACE
2024 · Lingfeng Diao, Chendong Wang, et al. · Journal of Gastroenterology and Hepatology · 19
Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
2023 · Xinhua Zou, Qingyu Xu, et al. · Advances in Therapy · 18
Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study☆
2024 · Dongdong Xia, Wei Bai, et al. · JHEP Reports · 17
PDF
Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance
2023 · Xinhua Zou, Qingyu Xu, et al. · Journal of Hepatocellular Carcinoma · 17
PDF
Optimal time point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolization
2022 · Dongdong Xia, Qiuhe Wang, et al. · European Radiology · 17
PDF
Works count: 65
Citation count: 3,638
H-index: 20
I10-index: 31
Year
Topic
Type